Welcome to our dedicated page for Nextcure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NextCure, Inc. (NASDAQ: NXTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on targeted therapies, including antibody-drug conjugates for cancer, NextCure uses its SEC filings to report material agreements, financing transactions, corporate actions and financial results.
Through Forms 8-K, NextCure reports events such as private placements of common stock and pre-funded warrants, reverse stock split approvals and implementation, strategic collaborations, executive changes and Annual Meeting voting results. For example, the company has filed 8-Ks describing a securities purchase agreement for a private placement that raised approximately $21.5 million in gross proceeds, the effectuation of a one-for-twelve reverse stock split, and the outcome of stockholder votes on director elections and other proposals.
Periodic reports such as 10-K annual reports and 10-Q quarterly reports (not reproduced here but referenced in the company’s press releases) typically include detailed discussions of NextCure’s pipeline, risk factors, research and development expenses, general and administrative costs and net losses. The company’s forward-looking statement and risk disclosures reference its limited operating history, lack of approved products, need for additional financing and clinical development uncertainties.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key terms, highlight important sections and help interpret complex legal and financial language. Real-time updates from EDGAR ensure that new NextCure filings appear promptly, including current reports on material events, equity issuances and corporate governance matters.
Investors can also use this page to track information relevant to capital structure and shareholder rights, such as reverse stock split details, amendments to the certificate of incorporation and unregistered sales of equity securities. Together, these filings offer a structured view of how NextCure manages its clinical-stage operations, finances its programs and complies with public company reporting requirements.
NextCure director Stephen W. Webster received a stock option grant on June 20, 2025, representing a significant insider transaction. Key details include:
- Granted 18,700 stock options to purchase common stock
- Exercise price set at $0.47 per share
- Options expire on June 19, 2035
- Full vesting occurs on the earlier of June 20, 2026 or the 2026 Annual Meeting
This director compensation grant suggests continued board engagement and alignment with shareholder interests through equity-based incentives. The relatively low exercise price compared to typical market prices for biotech stocks may indicate current market challenges or strategic considerations in retention of board talent.
NextCure, Inc. (NXTC) – Form 4 insider filing
On 24 June 2025, director Ellen Feigal filed a Form 4 reporting the grant of a stock option on 20 June 2025. The option covers 18,700 shares of common stock at an exercise price of $0.47 per share. It vests in full on the earlier of 20 June 2026 or the date of NextCure’s 2026 Annual Meeting of Stockholders and carries an expiration date of 19 June 2035. Ownership is reported as direct.
No open-market purchases or sales of common shares were disclosed, and no additional derivative or non-derivative transactions were listed. After the grant, Dr. Feigal’s beneficial ownership consists solely of these 18,700 option shares.
The filing represents a routine equity incentive award to a director and does not convey new operational or financial performance data.